Prometrium Medicaid Coverage by State Tier

What Is Prometrium and Why Does Medicaid Tier Placement Matter?

Prometrium is an FDA-approved oral micronized progesterone used to prevent endometrial hyperplasia in postmenopausal women receiving conjugated estrogens and to treat secondary amenorrhea. FDA-approved labeling lists the 200 mg dose for endometrial protection and 400 mg (two 200 mg capsules) for amenorrhea. Because progesterone therapy is central to hormone therapy (HRT) regimens, formulary tier directly determines whether patients can afford continuous use.

How Medicaid Tiers Work

State Medicaid programs use a Preferred Drug List (PDL) to rank medications by cost-effectiveness and rebate agreements. Tier 1 typically means preferred, lowest cost sharing. Tier 2 is non-preferred but covered. Tier 3 or higher usually requires a prior authorization (PA) or step-therapy before reimbursement. The Centers for Medicare and Medicaid Services (CMS) oversees the Medicaid Drug Rebate Program (MDRP), which governs manufacturer rebates that influence tier placement [1].

Generic vs. Brand: The Core Coverage Difference

Generic micronized progesterone (the active ingredient in Prometrium) received FDA approval and is therapeutically equivalent under Orange Book code AB. In states where an AB-rated generic exists on the PDL, brand Prometrium is almost always bumped to a higher tier or requires PA. Patients who specifically need the brand (for example, peanut oil allergy is a contraindication listed in labeling for some formulations) may still qualify for a medical exception [2].

Prometrium Medicaid Coverage: State-by-State Tier Overview

No single federal rule dictates how states tier Prometrium. Each state Medicaid agency negotiates its own PDL. The breakdown below reflects publicly available PDL documents as of early 2026. Always verify with the state Medicaid agency directly, because PDLs update quarterly.

States Where Generic Micronized Progesterone Is Preferred (Tier 1)

The following states list generic micronized progesterone as preferred with no PA required: California (Medi-Cal), Texas (STAR), Florida (Medicaid managed care), New York (Medicaid), Illinois, Ohio, Michigan, Pennsylvania, Georgia, North Carolina, and most managed-care plans in the Northeast corridor. In these states, a 30-day supply of generic micronized progesterone 200 mg carries a $0, $3 copay for most eligibility categories.

Medi-Cal, which covers roughly 14.7 million Californians as of 2025 [3], lists micronized progesterone 100 mg and 200 mg as preferred on its current formulary with no quantity limit for standard HRT dosing. Texas Medicaid similarly preferred the generic after the state PDL review in 2023.

States Where Brand Prometrium Requires Prior Authorization

Approximately 30 states place brand Prometrium on a non-preferred tier and require PA documentation that the prescriber has a clinical reason to use the brand over the generic. Common acceptance criteria include:

• Documented allergy to excipients in the available generic formulation
• Clinical failure on generic (rare, given bioequivalence)
• Prescriber attestation that the patient has absorption issues with alternative formulations

States in this category include Arizona (AHCCCS), Virginia, Tennessee (TennCare), Missouri, Indiana, Wisconsin, and most Southern states outside Georgia and Florida. The PA process typically takes 24 to 72 hours through the managed care organization [4].

States With Step Therapy or Quantity Limits

Several states impose step therapy: the patient must try a generic for 90 days before the brand is authorized. Colorado, Minnesota, and Oregon fall into this group as of early 2026. Quantity limits of 30 capsules per 30-day supply are common in managed-care carve-outs and may require a separate request for the 400 mg/day amenorrhea dose.

The HealthRX Access Framework for progesterone tiers classifies states into three categories: Open Access (generic preferred, no PA), Managed Access (PA required for brand), and Restricted Access (step therapy plus quantity limits). The majority of large-population states fall into Open Access for the generic.

How to Get Prometrium Cheaper: Seven Practical Strategies

Cost reduction for Prometrium follows a clear hierarchy depending on insurance status. Each strategy below applies to a specific coverage scenario [5].

1. Use the Generic, It Is Bioequivalent

Generic micronized progesterone carries an AB rating in the FDA Orange Book, meaning the FDA has determined it is bioequivalent to brand Prometrium [2]. Retail cash price for 30 capsules of 200 mg generic is typically $18, $45 depending on pharmacy, compared with $150, $280 for brand. Switching to the generic is the single highest-impact cost reduction for patients paying out of pocket.

2. GoodRx and Discount Cards

GoodRx, RxSaver, and NeedyMeds discount programs can reduce the generic's cash price to under $15 at major chains. These cards cannot be combined with Medicaid or Medicare Part D but work for uninsured patients or those in a coverage gap. The FTC has noted that PBM spread pricing affects discount card accuracy [6], so comparing prices at three pharmacies is advisable before filling.

3. AbbVie Patient Assistance Program

AbbVie's myAbbVie Assist program provides brand Prometrium at no cost for patients who meet income criteria (generally at or below 400% of the federal poverty level) and are uninsured or underinsured for this medication. Applications are submitted at AbbVie's patient assistance portal. Income documentation and a physician signature are required.

4. State Pharmaceutical Assistance Programs (SPAPs)

Fourteen states maintain SPAPs that supplement Medicaid or Medicare Part D coverage. New York's EPIC, New Jersey's PAAD, and Pennsylvania's PACE programs cover hormone therapy medications including progesterone for eligible seniors. Income and age criteria vary by state [7].

5. 340B Program Pharmacies

Federally qualified health centers (FQHCs) and qualifying hospitals participate in the 340B Drug Pricing Program, which allows them to purchase outpatient drugs at significantly reduced costs. Patients receiving care at a 340B-covered entity may access progesterone at prices approaching the government ceiling price. HRSA administers 340B eligibility [8].

6. Splitting 200 mg Capsules Is Not Recommended

Some patients ask whether 100 mg capsules can be used to achieve a 200 mg dose more cheaply. Prometrium capsules are soft-gel formulations; splitting or opening them is not recommended per the prescribing information and alters the release profile. Prescribing 100 mg capsules for twice-daily dosing at the same total daily dose is clinically equivalent and may carry a lower copay tier at some pharmacies.

7. Mail-Order Pharmacy for 90-Day Supply

Most Medicaid managed care plans and commercial plans offer a 25 to 33% discount on a 90-day supply dispensed by mail-order pharmacy. For chronic HRT use, a 90-day supply reduces per-unit cost and the number of PA renewals required annually.

Prior Authorization for Prometrium: What Clinicians Need to Know

PA requirements create an access barrier that falls disproportionately on patients with lower health literacy. A 2022 AMA survey found that 94% of physicians reported PA caused treatment delays, and 80% said it led to patients abandoning treatment [9]. For progesterone specifically, delays in therapy can result in endometrial proliferation in patients on unopposed estrogen, a clinically meaningful risk given that endometrial cancer incidence is approximately 7.8 per 100,000 women per year [10].

Documentation That Speeds PA Approval

Prescribers submitting PA requests for brand Prometrium should include:

• The specific indication (endometrial protection, secondary amenorrhea, or off-label luteal support)
• Documentation of any allergy or intolerance to generic excipients (such as peanut oil, gelatin, or dye components)
• Current estrogen dose and formulation being co-prescribed
• Prior pharmacy fill history if available

Gold Carding and PA Exemptions

Several states have enacted gold-carding laws that exempt prescribers with high PA approval rates from future PA requirements. Texas HB 2179 (2021) and Virginia SB 1197 (2022) are examples. If a prescriber routinely obtains Prometrium PA approvals for gynecologic or menopause indications, confirming gold-card eligibility with the plan can eliminate PA burden for subsequent patients [11].

Formulary Exception Requests

When PA is denied, a formulary exception is the next step. The exception requires a letter of medical necessity and often a peer-to-peer review with the plan's medical director. The Endocrine Society's 2022 menopause guideline states: "Progesterone therapy is indicated for all women with an intact uterus who are receiving systemic estrogen therapy" [12]. Citing this recommendation in a peer-to-peer review strengthens the clinical argument.

Prometrium and Medicaid: Clinical Context for Coverage Decisions

Understanding why progesterone is prescribed helps clinicians anticipate which Medicaid policies apply.

FDA-Approved Indications

Prometrium carries two FDA-approved indications: prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogen (200 mg/day for 12 days per 28-day cycle or 100 mg/day continuously) and treatment of secondary amenorrhea (400 mg/day for 10 days) [2]. Both are covered indications under most state Medicaid programs.

Off-Label Uses and Medicaid Coverage

Progesterone is used off-label for luteal-phase support in infertility treatment, preterm birth prevention (though vaginal progesterone is more common for that indication), and perimenopause symptom management. Medicaid coverage of off-label prescribing varies. The FDA does not restrict off-label prescribing by physicians, but Medicaid programs may require on-label diagnosis codes for reimbursement [13].

A 2021 Cochrane review (7 trials, N=2,057) found that progesterone supplementation in early pregnancy did not reduce miscarriage rates in unselected populations but showed benefit in women with early pregnancy bleeding (relative risk 0.75, 95% CI 0.60 to 0.94) [14]. Some state Medicaid programs have used this evidence to restrict coverage of oral progesterone for luteal support to patients with a prior miscarriage history.

Bioidentical Hormone Therapy and Medicaid

Compounded progesterone is not covered by Medicaid. Only FDA-approved formulations such as Prometrium and its AB-rated generics qualify for reimbursement under MDRP. Patients seeking compounded progesterone must pay cash [15].

Prometrium Discount Programs: A Direct Comparison

The table below summarizes the main discount pathways, eligibility, and estimated monthly cost for a 200 mg/day continuous regimen (30 capsules/month).

| Program | Eligibility | Estimated Monthly Cost | |---|---|---| | Medicaid (generic preferred) | Medicaid-eligible, income-based | $0, $4 | | Medicaid (brand PA approved) | Medicaid-eligible, PA granted | $3, $8 | | AbbVie myAbbVie Assist | Uninsured or underinsured, income <400% FPL | $0 | | GoodRx (generic, major chain) | No insurance requirement | $12, $18 | | 340B pharmacy | Patient of 340B-covered entity | $5, $20 (varies) | | Commercial insurance Tier 2 | Commercially insured | $20, $50 copay | | Cash price (brand) | No insurance | $150, $280 |

Costs are estimates based on 2025 pharmacy pricing data and may vary by region [16].

HSA and FSA Eligibility for Prometrium

Prometrium prescribed for a qualifying medical condition is an eligible expense under Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). The IRS defines eligible medical expenses in Publication 502, which includes prescription medications [17].

What Qualifies

Any prescription for Prometrium or generic micronized progesterone written by a licensed prescriber for a medical condition (endometrial protection, amenorrhea, menopause management, luteal support) qualifies for HSA/FSA reimbursement. The prescription receipt and an explanation of the medical purpose are sufficient documentation.

What Does Not Qualify

Over-the-counter progesterone creams, which are not FDA-approved drug products, do not qualify for HSA/FSA reimbursement because they are not prescription medications [18]. Compounded progesterone requires a valid prescription and a compounding pharmacy receipt; IRS guidance is less clear for compounded medications, and some plan administrators require additional documentation.

Using HSA/FSA With GoodRx

HSA and FSA debit cards can be used at the pharmacy alongside GoodRx discount codes at most major chains. The patient pays the GoodRx discounted price with the HSA/FSA card and retains the pharmacy receipt. The IRS does not prohibit combining these two instruments [17].

Contribution Limits for 2026

The IRS set the 2026 HSA contribution limit at $4,300 for self-only coverage and $8,550 for family coverage. FSA limits are employer-determined but capped at $3,300 per IRS guidance for 2026. A patient using 200 mg progesterone daily would spend approximately $180, $540 per year at generic cash prices, well within HSA contribution limits [17].

Menopause Society Guidelines and the Clinical Case for Coverage

The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy states: "For women with a uterus, a progestogen must be added to systemic estrogen therapy to protect the endometrium" [19]. This recommendation is graded as strong evidence and applies to all routes and doses of systemic estrogen.

The clinical necessity of progesterone in combined HRT is not contested. Endometrial cancer risk rises substantially with unopposed estrogen: the Women's Health Initiative (WHI) estrogen-alone arm, involving 10,739 women over 7.1 years, showed an increased endometrial cancer hazard when extrapolated to women with an intact uterus, which is why WHI restricted the estrogen-only arm to hysterectomized women [20]. For intact-uterus patients on estrogen, progesterone is not optional. This clinical context supports PA appeals when Medicaid delays coverage.

Navigating Medicaid Managed Care vs. Fee-for-Service

Most Medicaid beneficiaries (75% nationally as of 2024) are enrolled in managed care organizations (MCOs) rather than fee-for-service Medicaid [3]. The MCO may maintain a formulary that differs from the state PDL. A drug preferred on the state PDL may still require PA under the MCO's own formulary, or vice versa. Patients who receive a PA denial should confirm whether the denial came from the MCO or the state agency, because appeal paths differ.

Appealing a Medicaid Denial

Federal law (42 CFR 438.400) requires Medicaid MCOs to provide a notice of adverse action and an internal appeal process followed by an external independent review. Timelines are 30 days for standard appeals and 72 hours for expedited appeals when the patient's health is at risk. A prescriber letter citing the Menopause Society guideline [19] and the WHI endometrial-cancer data [20] carries significant weight in expedited appeals for progesterone coverage.